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ABSTRACT 39 
 Contemporary vaccine development relies less on empirical methods of vaccine 40 
construction, and now employs a powerful array of precise engineering strategies to construct 41 
immunogenic live vaccines.  In this review, we will survey various engineering techniques used 42 
to create attenuated vaccines, with an emphasis on recent advances and insights.  We will 43 
further explore the adaptation of attenuated strains to create multivalent vaccine platforms for 44 
immunization against multiple unrelated pathogens.  These carrier vaccines are engineered to 45 
deliver sufficient levels of protective antigens to appropriate lymphoid inductive sites to elicit 46 
both carrier-specific and foreign antigen-specific immunity.  Although many of these 47 
technologies were originally developed for use in Salmonella vaccines, application of the 48 
essential logic of these approaches will be extended to development of other enteric vaccines 49 
where possible.  A central theme driving our discussion will stress that the ultimate success of 50 
an engineered vaccine rests on achieving the proper balance between attenuation and 51 
immunogenicity.  Achieving this balance will avoid over-activation of inflammatory responses, 52 
which results in unacceptable reactogenicity, but will retain sufficient metabolic fitness to enable 53 
the live vaccine to reach deep tissue inductive sites and trigger protective immunity.  The 54 
breadth of examples presented herein will clearly demonstrate that genetic engineering offers 55 
the potential for rapidly propelling vaccine development forward into novel applications and 56 
therapies which will significantly expand the role of vaccines in public health.  57 
58 
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INTRODUCTION 59 
 The recent explosion in the availability of genomic sequences for a wide variety of 60 
pathogenic organisms, coupled with a rapid advance in powerful genetic engineering 61 
technologies, now offers the opportunity of efficiently developing highly immunogenic and 62 
protective vaccines against a wide variety of diseases.  The pathogens against which these 63 
vaccines are developed may be of viral, bacterial, parasitic, or fungal origin, and the resulting 64 
vaccines can be engineered either for animal or human vaccination.  In this review, we will focus 65 
on the engineering of live bacterial vaccines, and we will use the genus Salmonella to illustrate 66 
engineering strategies, which can in principle be applied to a variety of bacterial pathogens for 67 
which relevant molecular biology and pathogenicity data are available.  A central theme of this 68 
review will be the importance of metabolic fitness and its impact on the immunogenicity and 69 
protective efficacy of live vaccines.  The application of engineering technologies to pathogens 70 
without careful consideration of the balance between attenuation and immune responses can 71 
yield vaccine candidates that have excellent safety characteristics but have lost the capacity to 72 
reach immunological effector sites and consequently fail to induce protective immunity.  73 
Strategies that have been recently developed to address this critical balance between safety 74 
and immunogenicity will be emphasized within this context of metabolic fitness. 75 
 76 
ENGINEERING of BACTERIA INTENDED AS HOMOLOGOUS VACCINES. 77 
Attenuating strategies targeting virulence and metabolism.  It is relatively easy to weaken 78 
pathogens and engineer safe candidate attenuated vaccines.  Given that these pathogens are 79 
exquisitely adapted to grow and replicate within their hosts, engineering disruptions in their 80 
intricate balance of metabolic and virulence mechanisms will certainly not require an inordinate 81 
amount of technical prowess to create attenuated strains.  However, assuring safety while still 82 
achieving the immunogenicity and protective efficacy required with live vaccines has proven to 83 
be a much more challenging proposition for vaccine development.  In cases where virulence 84 
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factors such as toxins have been clearly defined, engineering deletions of such toxins has 85 
proven to be quite successful in creating effective vaccines.  Complete deletion of virulence 86 
genes, rather than introduction of inactivating point mutations, is required to ensure that the 87 
likelihood of reversion of the vaccine candidate back to a wildtype pathogen is very low; to 88 
further reduce the possibility of reversion, introduction of one or more additional attenuating 89 
deletions is usually carried out as well.  This early strategy for vaccine design was successfully 90 
applied by Tacket et al. almost a decade ago in the construction of an attenuated live cholera 91 
vaccine [1].  To accomplish this, the wildtype V. cholerae classical Inaba strain 569B was 92 
engineered for removal of both the catalytic subunit of cholera enterotoxin, as well as deletion of 93 
a putative hemolysin virulence factor.  When tested in volunteers, this vaccine was found to be 94 
safe and highly immunogenic, with a protective efficacy of 91% against moderate to severe 95 
diarrhea and 80% against any diarrhea, after challenge with 105 colony forming units (CFUs) of 96 
fully virulent Vibrio cholerae. 97 
 In the case of Salmonella vaccines, attenuation of wildtype strains has focused both on 98 
deletion of virulence factors as well as disruption of metabolic pathways, and the two serovars 99 
of Salmonella with which most vaccine constructions have been carried out are Salmonella 100 
enterica serovars Typhimurium and Typhi.  S. Typhimurium typically causes a self-limiting 101 
gastroenteritis in humans while S. Typhi is the etiologic agent of typhoid fever.  In both serovars, 102 
virulence factors have been found to be chromosomally encoded within clusters called 103 
Salmonella Pathogenicity Islands (SPIs) which play critical roles in the manifestation of disease 104 
[2].  Much attention has been devoted in particular to two distinct pathogenicity islands that 105 
encode type III secretion systems (T3SS) that inject virulence proteins called effectors into 106 
target eukaryotic cells, disrupting normal host cellular functions and facilitating Salmonella 107 
invasion and systemic disease [3-5].  The SPI-1 T3SS externally targets eukaryotic host cells 108 
and injects effectors that trigger actin rearrangements to enhance uptake of Salmonella.  Then 109 
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using the SPI-2 T3SS, internalized Salmonella are able to inject additional effector proteins into 110 
the cytoplasm essential for bacterial intracellular survival and replication [6]. 111 
 In a study reported by Hindle et al. [7], attenuated vaccine candidates from both S. 112 
Typhimurium (designated WT05) and S. Typhi (designated M01ZH09) were engineered such 113 
that delivery of all SPI-2 effectors was disrupted by deletion of a critical structural protein ssaV 114 
involved in the assembly of the effector injectisome apparatus.  This deletion mutation was 115 
accompanied by a further deletion in aroC involved in the aromatic amino acid biosynthesis 116 
pathway, creating candidate vaccine strains which were then compared in a Phase 1 dose-117 
escalating clinical trial [7].  Both strains were shown to be safe, with negligible clinical symptoms 118 
and no vaccine organisms detected in the blood.  The S. Typhi M01ZH09 vaccine was shed 119 
from the majority of volunteers for 3 days. However, the attenuated S. Typhimurium WT05 strain 120 
established an unacceptably persistent colonization of volunteers with shedding for up to 3 121 
weeks, and this strain was not pursued further.  When evaluated in Phase 2 clinical trials [8], 122 
single oral doses of M01ZH09 up to 1.7 x 1010 CFUs were found to be safe and immunogenic, 123 
with 97.4% of subjects responding to vaccination with either IgG or IgA responses to S. Typhi 124 
LPS, and 92.1% of those receiving a dose of 7.5 x 109 CFUs having a positive S. Typhi LPS-125 
specific ELISPOT response. 126 
Balancing safety and immunogenicity.  Live vaccines that are insufficiently attenuated elicit 127 
unacceptable clinically defined adverse events in vaccinees and are considered unacceptably 128 
reactogenic.  As work with the attenuated M01ZH09 S. Typhi vaccine illustrates, attenuation 129 
strategies targeting both virulence determinants and metabolic factors can be quite effective for 130 
constructing safe and immunogenic live vaccines that perform well in clinical trials.  However, 131 
care must be taken to ensure that metabolic attenuation strategies do not result in the over-132 
attenuation of vaccines, with subsequent loss of immunogenicity resulting from the crippling of 133 
metabolic fitness of the live vaccine.  Genetic inactivation of too many critical genes, or 134 
inappropriate selection of targets, can result in vaccine candidates that fail to colonize a host 135 
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sufficiently to engage innate and acquired immunity, and elicit durable protection.  We have 136 
previously reviewed the results of clinical trials conducted with attenuated S. Typhi candidate 137 
vaccines, and noticed a striking relationship between reactogenicity and immunogenicity [9], 138 
which we illustrate schematically in Figure 1.  Fully virulent strains, as well as vaccine 139 
candidates, which are insufficiently attenuated elicit unacceptable clinical symptoms (i.e. highly 140 
reactogenic) but also tend to be highly immunogenic (Figure 1A).  Vaccines that have been 141 
genetically engineered to minimize reactogenicity may become insufficiently immunogenic 142 
(Figure 1B).  Ideally, the most promising live vaccines that perform well in clinical trials will 143 
achieve a delicate balance between reactogenicity and immunogenicity (Figure 1C). 144 
 This concept is clearly illustrated by a series of attenuated S. Typhi candidate oral 145 
vaccines engineered from the wildtype strain CDC10-80, all carrying a deletion in the aroA gene 146 
critical to the aromatic amino acid biosynthesis pathway.  When coupled with an additional 147 
mutation in aroD, the resulting aroA aroD strain proved to be insufficiently attenuated but 148 
highly immunogenic (Figure 1A) [10] .  When the triple deletion mutant aroA aroD htrA was 149 
constructed (by further deletion of htrA encoding a heat-shock serine protease), safety improved 150 
at lower oral dosage levels but immunogenicity declined (Figure 1B); at higher oral doses which 151 
improved immunogenicity, reactogenicity (i.e. fever and bacteremia) was unacceptably high 152 
(Figure 1A) [10].  Combining aroA with deletions in either purA (involved in the purine 153 
biosynthesis pathway), or phoP/phoQ (a two-component environmental regulatory system of 154 
virulence in Salmonella) dramatically reduced both reactogenicity and immunogenicity (Figure 155 
1B) [11;12].  It was only when the phoP/phoQ deletion mutation alone was introduced into a 156 
different parent strain of S. Typhi (Ty2) that it became possible to balance reactogenicity with 157 
immunogenicity at high oral dosage levels (Figure 1C) to induce vaccine-specific immunity [13].  158 
These observations clearly illustrate that the engineering of an attenuated live bacterial vaccine 159 
requires a carefully crafted balance between attenuation and immunogenicity that is not always 160 
attainable by deliberate engineering and may sometimes only be achieved by trial and error, 161 
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with clinical trials ultimately determining the fate of vaccines that animal models can only 162 
suggest as promising candidates. 163 
 Over-attenuation and the subsequent failure of engineered strains to reach appropriate 164 
immune inductive sites was encountered by Kong et al. [14] with efforts to construct attenuated 165 
strains of S. Typhimurium by engineering modifications to lipopolysaccharide (LPS).  LPS is the 166 
major component of the outer membrane of Salmonella, and is a key virulence determinant that 167 
confers protection against complement activation and killing by macrophages [15].  LPS is 168 
comprised of a lipid A membrane anchor, a core oligosaccharide, and the outer O-antigen which 169 
defines the various serovars of Salmonella.  Since the enzymatic pathways involved in LPS 170 
synthesis are well characterized for Salmonella [16], Kong et al. undertook a systematic 171 
analysis of the effects of engineering truncations in O-antigen and core sugars of LPS on the 172 
virulence and immunogenicity of S. Typhimurium.  All of the resulting mutants tested were 173 
shown to be avirulent in mice; the lethal dose of organisms resulting in death for 50% of a group 174 
of orally challenged mice (LD50) was determined to be >109 CFU for all engineered strains.  A 175 
clear relationship emerged between the extent of truncating LPS and deep tissue colonization of 176 
mice, and it was determined that deletion of LPS into the core oligosaccharide region resulted in 177 
a severe drop in colonization while preservation of at least one sugar residue at the terminus of 178 
the O-antigen was sufficient to enable significant colonization of the Peyer’s patches, liver, and 179 
spleen of orally and intranasally immunized mice.  It was also conclusively demonstrated that 180 
strains which successfully colonized deep tissues induced excellent serum antibody responses 181 
against S. Typhimurium LPS [14]. 182 
Attenuation achieved by addition as well as subtraction. Up to this point, we have 183 
considered only the construction of attenuated vaccine strains by deletion of native endogenous 184 
functions, whether they be virulence determinants or metabolic factors.  However, novel 185 
approaches have recently been reported in which fully functional factors from foreign bacteria 186 
have been engineered into a pathogenic strain with the intention of disrupting pathogenicity and 187 
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improving innate and adaptive immunity.  This intriguing strategy has been applied to the 188 
remodeling of the lipid A moiety of LPS which is responsible for the endotoxic activity of enteric 189 
pathogens such as Salmonella. The lipid A moiety of LPS stimulates a strong innate immune 190 
response via stimulation of the Toll-like receptor 4 (TLR4)-MD2 complex, and triggers a 191 
vigorous inflammatory response that contributes to the reactogenicity of Salmonella.  The 192 
endotoxicity of lipid A is dependent on the number and length of hydrophobic acyl side chains 193 
anchoring lipid A into the outer membrane [17], as well as the phosphorylation state of the 194 
disaccharide backbone [18].  Lipid A is typically biphosphorylated in Salmonella, which enables 195 
full induction of innate immunity through stimulation of TLR4-MD2.  Kong et al. [19] reported that 196 
insertion of foreign genes encoding non-homologous phosphatases into S. Typhimurium 197 
resulted in attenuated strains with increased sensitivity to the bile salt deoxycholate and 198 
reduced ability to colonize the deep tissues of mice after oral immunization.  The LD50 for 199 
engineered strains producing monophosphorylated lipid A increased 3-4 logs while strains with 200 
totally non-phosphorylated lipid A were completely avirulent in mice. Despite the fact that 201 
monophosphorylated strains still retained some virulence at high doses, this strategy may still 202 
prove effective in reducing reactogenicity at high doses when combined with other attenuating 203 
deletions in metabolic pathways. 204 
 LPS-remodeling strategies have also proven to be useful in the engineering of 205 
attenuated strains of Yersinia pestis, the causative agent of plague.  The lipid A membrane 206 
anchor of Y. pestis LPS carries six hydrophobic side chains (hexa-acylated) when residing 207 
outside its human host, but down-regulates acylation to a tetra-acylated form after infection in 208 
response to the increase in temperature from ambient 26°C to 37°C.  Hexa-acylated LPS is a 209 
potent TLR4 agonist while tetra-acylated LPS binds poorly to TLR4-MD2, resulting in a 210 
reduction in inflammatory responses. When Y. pestis was engineered for chromosomal 211 
expression of a non-homologous acyl-transferase, forcing expression of hexa-acylated LPS at 212 
37°C, the resulting strains were highly attenuated yet immunogenic when this mutation was 213 
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coupled with a metabolic deletion in a sugar utilization pathway.  Mice immunized 214 
subcutaneously or intranasally with this construct were protected against both subcutaneous 215 
and intranasal challenge with fully virulent Y. pestis [20].  Interestingly, when attempts were 216 
made to further attenuate engineered plague vaccines by reducing the phosphorylation state of 217 
lipid A using a non-homologous phosphatase (an approach that proved successful when applied 218 
to Salmonella), this strategy was unsuccessful with Y. pestis [21]. 219 
Attenuation through replication.  Until recently, all attenuating strategies developed to date 220 
had begun with a fully virulent pathogen and engineered insertion or deletion mutations into a 221 
wildtype strain with the goal of creating a vaccine candidate that was sufficiently attenuated to 222 
ensure safety but sufficiently robust to confer immunogenicity.  A novel shift in this established 223 
paradigm was first reported by Curtiss et al. in 2009 [22], in which candidate vaccines were 224 
engineered to be fully virulent at the time of immunization, and to become attenuated as they 225 
replicated within the host.  This attenuation strategy effectively avoids the over-attenuation of 226 
vaccines prior to reaching appropriate immune induction sites since the intricate balance 227 
between virulence factors and metabolic pathways of the engineered pathogen remain 228 
unchanged until limited replication within the host gradually manifests the attenuated state.  This 229 
biological transition from a fully virulent organism to an attenuated vaccine is referred to as a 230 
regulated delayed attenuation phenotype (RDAP), and is engineered to be dependent on the 231 
intracellular concentration of the sugar arabinose at the time of immunization.  To accomplish 232 
this requires the genetic targeting of several key metabolic chromosomal loci involved in the 233 
intracellular replication and survival of Salmonella, whose transcription levels are re-engineered 234 
to be controlled by the arabinose activator/repressor AraC [23].  In the presence of arabinose, 235 
AraC binds arabinose and subsequently activates transcription of any genes transcriptionally 236 
controlled by the arabinose promoter PBAD; in the absence of arabinose, AraC is incapable of 237 
activating PBAD and transcription ceases.  Given that arabinose concentrations available to 238 
vaccine organisms after immunization will be insufficient to ensure synthesis of these critical 239 
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regulatory proteins in vivo, loss of function will increase with every round of replication of 240 
vaccine organisms until maximum attenuation occurs.  Using this transcriptional control system, 241 
gene cassettes encoding AraC linked to PBAD were engineered by Curtiss et al. to replace the 242 
natural promoters controlling genes involved in iron regulation (fur), catabolite repression (crp), 243 
magnesium regulation of virulence factors (phoPQ), and stationary-phase protein expression 244 
(rpoS).  All engineered strains were confirmed in vitro not to grow in the absence of arabinose 245 
on otherwise rich bacteriologic media.  While strains carrying individually targeted regulatory 246 
genes proved to be insufficiently attenuated in the mouse model at elevated oral doses [22], 247 
later combinations of these mutations proved to yield highly immunogenic live vaccines in orally 248 
immunized mice [24].  This attenuating strategy was recently introduced into S. Typhi strains in 249 
anticipation of Phase 1 clinical trials [25] which have now been completed; candidate RDAP 250 
vaccine strains were proven to be safe and immunogenic in orally vaccinated volunteers, 251 
demonstrating that properly attenuated live S. Typhi vaccines such as RDAP vaccines can 252 
retain the ability to undergo limited replication within humans without eliciting clinical symptoms 253 
[26] .  254 
 255 
FURTHER ENGINEERING of ATTENUATED STRAINS AS CARRIER VACCINES FOR 256 
DELIVERY of FOREIGN ANTIGENS. 257 
Foreign gene expression and metabolic stress.  It is clear from efforts to construct 258 
attenuated live vaccines that disruption of the metabolism of a pathogen results in attenuation 259 
and over-attenuation results in loss of immunogenicity.  It therefore follows that attempts to 260 
further engineer additional expression technologies into a candidate vaccine, which may further 261 
impact already attenuated metabolic pathways, may destroy the efficacy of the resulting live 262 
vaccine without sufficient attention being paid to maintaining the fitness of the vaccine strain.  263 
This becomes a serious consideration in the development of live multivalent vaccines (hereafter 264 
referred to as carrier vaccines) designed for immunization against several unrelated pathogens 265 
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by delivering additional protective antigens to the immune system. The efficacy of any live 266 
carrier vaccine rests with its ability to present sufficient foreign antigen to the human immune 267 
system to elicit the desired protective immune responses.  However, unregulated expression of 268 
foreign antigens diverts precious energy and metabolic resources away from the metabolism of 269 
the vaccine and into synthesis of proteins from which the vaccine derives no selective 270 
advantage either in growth or replication.  As has been observed in clinical trials with RDAP 271 
vaccines, after immunization, live vaccines undergo a limited number of replications which allow 272 
limited colonization of lymphoid inductive sites to induce immune responses; further 273 
compromise of the metabolism of the live vaccine by unrestricted synthesis of foreign antigens 274 
will inevitably over-attenuate the vaccine and destroy immunogenicity.  275 
 The inevitable effect of foreign antigen synthesis on the metabolism of a live carrier 276 
vaccine could in principle be exploited to reduce the reactogenicity and improve the safety of a 277 
candidate vaccine with some residual reactogenicity (Figure 1D).  While it is clear that over-278 
expression of a foreign antigen will over-attenuate the resulting carrier vaccine (Figure 1E), 279 
careful attention to appropriate induction of foreign antigen synthesis, either by regulating the 280 
timing, level of synthesis, or processing of the antigen could in principle restore the balance 281 
between attenuation and immunogenicity to create a carrier vaccine with both excellent safety 282 
and immunogenicity (Figure 1F). 283 
 The concept of over-expression of foreign antigens leading to attenuation of otherwise 284 
metabolically fit organisms has been intentionally exploited recently to create carrier vaccines 285 
directly from wildtype pathogens, a strategy referred to as Attenuating Gene Expression (AGE) 286 
[27].  Support for this concept comes from the observation that over-expression of endogenous 287 
native proteins such as flagella severely attenuates wildtype S. Typhimurium by disrupting the 288 
bacterial outer membrane, resulting in elevated susceptibility to bile and an inability to replicate 289 
within murine macrophages.  Although attenuated, these engineered strains remained 290 
immunogenic and conferred excellent protection against homologous challenge with fully 291 
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virulent S. Typhimurium [28]. Over-expression of native proteins was also confirmed to 292 
attenuate Y. pestis, wherein over-expression the caf operon, encoding the essential virulence 293 
capsule F1, was observed to dramatically reduce both intra-macrophage survival rates and the 294 
infectivity of otherwise fully virulent Y. pestis [29].  Over-expression of the caf operon was 295 
subsequently engineered as a foreign antigen gene cassette into wildtype S. Typhimurium, 296 
resulting in a carrier strain with severely reduced survival in murine macrophages and complete 297 
loss of virulence in mice.  As expected, if expression of the caf operon was tightly regulated 298 
using the native Y. pestis temperature regulated promoter, the resulting carrier strain displayed 299 
excellent expression of the F1 capsule but also retained full virulence in mice [29].  Since such 300 
over-expression of foreign proteins clearly exerts metabolic pressure on the carrier strain, a 301 
selective advantage will arise for spontaneous deletion mutations arising that destroy foreign 302 
antigen synthesis.  Therefore, reliance solely on the AGE strategy for engineering carrier 303 
vaccines will not be adequate and will require additional independently attenuating deletions to 304 
ensure safety. 305 
Metabolic stress and instability of expression plasmids.  Expression and delivery of foreign 306 
antigens by attenuated carrier vaccines can be accomplished either by plasmid-mediated 307 
expression or by integration of foreign genes into the vaccine chromosome.  When using 308 
multicopy expression plasmids, induction of antigen expression can introduce sufficient 309 
metabolic stress upon the carrier vaccine to result in a selective advantage for plasmid loss, 310 
which eliminates this metabolic stress and allows a restoration of fitness.  If rapid plasmid loss 311 
occurs in vivo following immunization, antigen-specific immunity will be lost as well.  Since the 312 
use of antibiotics for plasmid maintenance (a practice commonly used under laboratory 313 
conditions) is of little use in vivo and is currently discouraged by the Food and Drug 314 
Administration for use with human oral vaccines, non-antibiotic strategies are needed for 315 
ensuring plasmid maintenance in vivo and enhancing antigen-specific immunity.  An effective 316 
yet simple solution to this dilemma was devised in which a gene encoding an essential function 317 
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within the carrier vaccine was deleted from the chromosome and placed instead on a multicopy 318 
expression plasmid.  Loss of the plasmid would then result in a non-viable carrier vaccine, 319 
thereby ensuring plasmid maintenance in vivo during limited replication and colonization of 320 
inductive lymphoid tissues.  When chromosomal targets for such deletions involve enzymatic 321 
functions whose metabolic products can be added to the growth medium during in vitro 322 
cultivation, construction of multivalent carrier vaccines becomes reasonably straightforward.  323 
This strategy was exploited by Galán et al. [30] more than two decades ago by targeting a 324 
metabolic pathway involved in the synthesis of the S. Typhimurium cell wall.  The enzyme 325 
aspartate β-semialdehyde dehydrogenase (Asd) is essential for the proper synthesis of the 326 
bacterial cell wall and several amino acids [31], and loss of Asd activity results in lysis of the 327 
bacterium resulting from an inability to correctly assemble the peptidoglycan layer of the cell 328 
wall.  Attenuated strains in which Asd-encoding plasmids have not yet been introduced can be 329 
efficiently propagated by adding the metabolite diaminopimelic acid (DAP) to the growth 330 
medium until Asd-stabilized plasmids have been introduced.  Using this plasmid stabilization 331 
strategy, attenuated strains of S. Typhimurium were constructed in which asd was encoded by 332 
high copy number plasmids, and the resulting carrier strains were evaluated for plasmid 333 
retention in orally immunized mice. For carrier strains recovered from deep tissues of 334 
immunized mice, 99% of recovered vaccine organisms retained Asd-stabilized expression 335 
plasmids in vivo (despite the very high copy number of these plasmids), compared to only 10% 336 
of vaccine organisms retaining unstabilized lower copy number conventional plasmids after 337 
recovery from mice [32].  338 
 This remarkably versatile strategy for plasmid maintenance was later expanded to 339 
include non-catalytic proteins such as the single-stranded binding protein (SSB) which is 340 
essential for DNA replication, recombination, and repair [33;34].  Since SSB produces no 341 
metabolic products that can be added to cultures in vitro, chromosomal deletion of ssb required 342 
the sequential use of temperature-sensitive suicide plasmids to establish this maintenance 343 
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system [35].  Use of SSB-stabilized plasmids in attenuated S. Typhi carrier vaccines ultimately 344 
showed that antibody responses elicited in mice against foreign antigens delivered by S. Typhi 345 
carrier vaccines were inversely related to the metabolic burden imposed by expression of the 346 
foreign antigen, and that these responses were improved when antigens were expressed from 347 
low-copy-number SSB-stabilized plasmids carried by less attenuated carrier vaccines [35]. 348 
Minimizing metabolic stress by synchronizing antigen expression with metabolism.  349 
Success with plasmid maintenance systems that essentially guarantee plasmid stability in vivo 350 
can quickly lead to additional problems with over-attenuation frequently associated with 351 
plasmid-based delivery of foreign proteins.  Due to the multicopy aspect of plasmids, when 352 
foreign genes are induced there is a rapid rise in antigen synthesis (Figure 2A) [36] which tends 353 
to slow growth rate and reduce the colonization capacity of the carrier vaccine due to the severe 354 
diversion of metabolic resources [37].  Over the years, vaccine developers have created a 355 
number of tools for reducing the effect of this antigen burst through tightly regulating control of 356 
the transcription, translation, and export of foreign antigens.  These techniques have been 357 
reviewed elsewhere in considerable detail by ourselves [38-40] and other groups [41;42], and 358 
will not be recapitulated here.  Slightly more unconventional efforts to minimize the effects of 359 
antigen burst have recently been reported in which an attempt is made to link the timing of 360 
antigen synthesis directly to the physiology of the carrier vaccine. 361 
 One way to link the synthesis of foreign antigens to vaccine physiology is an extension 362 
of the technique of regulated delayed attenuation, in which the timing of antigen synthesis is 363 
intimately linked to replication of the vaccine in vivo.  This strategy is referred to as regulated 364 
delayed antigen synthesis (RDAS, Figure 2B) [43], and was created by engineering 365 
modifications to the well characterized lactose repressor (LacI) transcriptional control system 366 
frequently employed to control foreign antigen synthesis [44].  In the absence of lactose or other 367 
synthetic sugar analogs, LacI binds to its cognate promoter and prevents transcription of the 368 
downstream open reading frame; the binding of LacI to lactose or synthetic analogs causes an 369 
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allosteric shift in LacI conformation which derepresses transcription, with subsequent 370 
commencement of foreign antigen synthesis.  By replacing the natural lacI promoter with an 371 
arabinose-controlled araC promoter, antigen synthesis is then linked to intracellular 372 
concentrations of arabinose, in a strategy similar to the previously discussed delayed 373 
attenuation system.  Antigen synthesis is then ultimately linked to the replication and growth rate 374 
of the bacterial strain, with diminishing intracellular concentrations of arabinose leading to a shift 375 
in protein synthesis away from LacI expression and towards an increase in foreign antigen 376 
synthesis (Figure 2B).  Such an approach would theoretically allow remarkable diversity in the 377 
timing of antigen delivery by a carrier vaccine.  Antigen production in vaccine organisms 378 
prepared in the presence of arabinose would be tightly repressed prior to immunization; after 379 
oral administration, transient exposure to lactose after immunization could enable a quick but 380 
temporary burst of foreign antigen production, with full and sustained induction occurring as the 381 
vaccine grows and colonizes lymphoid tissues and intracellular LacI concentrations drop.  382 
 A thorough characterization of plasmid-based regulated delayed antigen synthesis in 383 
attenuated S. Typhimurium carrier vaccines was described by Wang et al. [43], and this work 384 
clearly demonstrated that the over-attenuating effects of poorly regulated antigen expression 385 
from multicopy plasmids could be effectively overcome by an arabinose-controlled LacI-386 
mediated antigen gene expression system.  When mice were orally immunized with RDAS 387 
carrier vaccines delivering a protective pneumococcal surface protein (PspA) antigen from 388 
Streptococcus pneumoniae, 52% of vaccinated animals were protected against challenge with 389 
fully virulent S. pneumoniae, while only 21% of mice receiving vaccines constitutively over-390 
expressing the foreign antigen were protected [43]. 391 
 In a related approach linking the timing of antigen synthesis directly to the physiology of 392 
the carrier vaccine, initial studies have demonstrated the feasibility of controlling the timing of 393 
foreign antigen expression encoded by chromosomally engineered expression cassettes, 394 
without the need for plasmids.  Although expression of foreign antigens exclusively from 395 
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chromosomally integrated gene cassettes offers the substantial advantage of minimizing any 396 
metabolic burden associated either with multicopy expression plasmids or the foreign antigens 397 
they encode, the challenge with this approach has been synthesizing sufficient levels of foreign 398 
antigen capable of eliciting relevant immune responses despite the significant drop in copy 399 
number of the cassettes encoding these antigens.  Using a cassette encoding the model foreign 400 
antigen green fluorescent protein (GFP), Wang et al. [36] described a novel chromosomal 401 
expression strategy designed to compensate for the inherent disadvantage of lower gene 402 
dosage (versus plasmid-based expression) by integrating a single GFP-encoding gene cassette 403 
into multiple chromosomal sites already inactivated in an attenuated S. Typhi vaccine candidate.  404 
Using GFP-encoding cassettes integrated into both guaBA (which displays growth-regulated 405 
transcriptional control of antigen synthesis [45]) and htrA (which displays transcriptional control 406 
of antigen synthesis in response to metabolic stress during growth [46]), cumulative synthesis of 407 
GFP from these two integration sites was observed to be superior to single integrations.  Most 408 
importantly, it was demonstrated that GFP expression increased in a growth phase-dependent 409 
manner, suggesting that foreign antigen synthesis could be “tuned” to the physiology of the 410 
carrier vaccine [36].  This promising chromosomal expression technology is currently being 411 
combined with plasmid-based expression from stabilized plasmids for delivery of several 412 
protective antigens from Y. pestis, delivered by a single multivalent S. Typhi carrier vaccine. 413 
Site of antigen delivery and subsequent immune response. In addition to tightly regulated 414 
expression of foreign antigens, it is now clear that the manner in which these antigens are 415 
delivered to the immune system can have a profound impact on the resulting immune 416 
responses and ultimate success of a carrier vaccine.  The induction and extent of mucosal, 417 
humoral, or cellular immunity can be significantly influenced by whether foreign antigens are 418 
expressed within the carrier vaccine or exported out of the live vaccine, as well as whether 419 
antigens are expressed prior to host cell invasion or delivered by intracellular carriers.  It is now 420 
reasonably well established that antigen-specific humoral immunity can increase significantly 421 
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when antigens are exported either to the carrier surface or extracellularly into the surrounding 422 
milieu, rather than remaining in the cytoplasm [47-49].  It has also been reported that cellular 423 
immunity to surface antigens delivered by intracellular carriers is superior to immunity targeting 424 
cytoplasmic antigens [50].  425 
 Cellular responses can also be improved by injection of foreign proteins from 426 
intracellular carrier vaccines into the cytoplasm of antigen-presenting cells via Salmonella type 427 
III secretion systems, a technique first described over a decade ago by Russmann et al [51].  428 
Hegazy et al. [52] have further developed this approach by conducting a methodical analysis of 429 
the translocation efficiency of a panel of SPI-2 effector proteins when used as carriers for 430 
antigenic passenger domains fused to the carboxyl terminus of the SPI-2 carrier.  They 431 
observed that for S. Typhimurium carrier vaccines delivering passenger domains of listeriolysin 432 
O (a protective antigen from Listeria monocytogenes) fused to SPI-2 effectors, translocation of 433 
fusions into murine bone marrow-derived dendritic cells displayed varying efficiencies in vitro, 434 
depending on the specific effector fusion involved.  However, in mice orally immunized with 435 
these carrier strains, stimulation of L. monocytogenes antigen-specific cytotoxic T-cells did not 436 
strictly correlate with in vitro translocation efficiencies. This disparity may be a reflection of 437 
artificial induction conditions used for in vitro expression, which may have little relevance to in 438 
vivo microenvironmental induction conditions.  However, it was clear from these studies that 439 
choosing the right SPI-2 effector for translocation of a vaccine antigen can elicit robust levels of 440 
cytotoxic immunity against intracellular pathogens. 441 
Antigen delivery by regulated lysis.  One rather extraordinary method for delivery of 442 
intracellular antigens to lymphoid inductive sites is through outright lysis of the carrier vaccine to 443 
release cytoplasmic contents including foreign proteins (depicted schematically in Figure 2C).  444 
Success with this approach will depend on the timing of lysis, which must occur as vaccine 445 
organisms are reaching inductive sites.  Since delayed attenuation technologies proved that it 446 
was possible to control the timing of induced attenuation to coincide with deep tissue 447 
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colonization and elicitation of protective immunity, it was considered plausible to adapt the 448 
delayed phenotype strategy to achieve delayed lysis of a carrier vaccine and test the 449 
immunogenicity of these novel constructs.  Successful testing of this delayed lysis strategy was 450 
first reported by Kong et al. [53] who genetically engineered a programmed lysis system based 451 
on arabinose-controlled production of two key enzymes involved in the synthesis and 452 
mechanical stability of the carrier vaccine cell wall.  Diaminopimelic acid and muramic acid are 453 
explicitly required to ensure the integrity of the peptidoglycan layer of the carrier vaccine cell 454 
wall, and synthesis of these two components requires enzymes encoded by chromosomal asd 455 
and murA genes respectively.  The requirement for synthesis of aspartate β-semialdehyde 456 
dehydrogenase (Asd) to ensure the integrity of the cell wall was first exploited for maintenance 457 
of plasmids delivering foreign antigens (described above), with lysis of the vaccine resulting 458 
from plasmid loss and cessation of Asd synthesis.  To ensure complete lysis of vaccine 459 
organisms and full release of cytoplasmic contents, arabinose-controlled synthesis of Asd was 460 
coupled with additional arabinose-controlled synthesis of MurA.  To establish exquisitely 461 
stringent regulation of Asd and MurA synthesis, an arabinose-regulated anti-sense RNA system 462 
was also engineered onto the antigen-expressing multicopy plasmid.  In the absence of 463 
arabinose, chromosomal transcription of both asd and murA ceased, as did transcription of an 464 
additional chromosomally encoded repressor of the anti-sense-RNA system. Therefore, 465 
cessation of both asd and murA transcription was simultaneously accompanied by induction of 466 
high levels of antisense RNA synthesized from the expression plasmid, effectively blocking 467 
residual translation from any lingering asd or murA transcripts.  These concerted activities lead 468 
to cell lysis and release of vaccine antigens [53].  In mice orally immunized with carrier vaccines 469 
engineered for constitutive periplasmic synthesis of the S. pneumoniae protective PspA antigen, 470 
coupled with delayed lysis to release PspA, excellent serum antibody responses against both 471 
the foreign antigen and carrier-specific outer membrane proteins were reported.  No viable 472 
vaccine organisms were detected in host tissues after three weeks, demonstrating that these 473 
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engineered strains were able to proliferate long enough to stimulate humoral immunity but were 474 
eventually completely cleared from the vaccinated host [53].  This last point may have relevance 475 
to previous clinical trials in which orally administered S. Typhimurium WT05 vaccine strains 476 
proved unacceptably attenuated and were shed for greater than three weeks from vaccinees [7]. 477 
 The development of the delayed lysis strategy for carrier vaccines paves the way for 478 
significant improvements in the use of carriers for delivery of DNA vaccines.  Although several 479 
early reports supported the feasibility of delivering DNA vaccines using attenuated carrier 480 
strains to elicit immune responses [54-56], attempts to expand this vaccination strategy have 481 
proven frustrating.  The use of delayed lysis to improve DNA vaccine delivery and ensuing 482 
immune responses has now been reported by Kong et al. [57].  In addition to the delayed lysis 483 
strategy, additional vaccine modifications required for successful delivery of the DNA vaccine 484 
involved: 1] increased expression of the SPI-1 activator HilA protein, resulting in a hyperinvasive 485 
phenotype for the carrier strain to improve intracellular delivery of the DNA vaccine, 2] 486 
inactivation of the SPI-2 effector protein SifA allowing Salmonella to escape from intracellular 487 
vacuoles into the target cell cytoplasm, 3] inactivation of additional SPI-2 effectors which 488 
normally induce apoptosis of eukaryotic cells by intracellular Salmonella, thereby allowing 489 
sufficient time for DNA vaccines to traffic to the nucleus, and 4] insertion of multiple DNA 490 
vaccine nuclear-targeting sequences to facilitate efficient delivery of the DNA vaccine to the 491 
target cell nucleus after cytoplasmic lysis of the carrier.  An optimized DNA vaccine encoding 492 
the influenza hemagglutinin (HA) protective antigen, delivered by an optimized delayed lysis S. 493 
Typhimurium carrier vaccine, induced complete protection in orally immunized mice against a 494 
lethal intranasal challenge with 100 LD50s of fully virulent influenza virus [57].  Given that DNA 495 
vaccines are virtually silent in carrier strains, plasmid-mediated metabolic attenuation of the 496 
carrier is significantly reduced, and such vaccines have great potential in applications for which 497 
conventional vaccination strategies have proven unsatisfactory. 498 
  499 
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NOVEL APPLICATIONS of ENGINEERED VACCINES. 500 
Engineered vaccines as “reagent strains”. Aside from the conventional deployment of 501 
engineered strains as live and carrier vaccines, several additional applications of these strains 502 
have arisen which bear mention, including use in conjugate vaccine development and novel 503 
approaches to cancer treatment and prevention.  Conjugate vaccines represent a versatile 504 
subunit vaccine strategy in which protective immunity can be targeted against capsular and 505 
outer membrane polysaccharides of a variety of Gram-negative bacteria.   Along with the 506 
burgeoning interest in conjugate vaccines against pathogenic bacteria comes the problem of 507 
economic and safe purification of the polysaccharide haptens and the carrier proteins from 508 
which the conjugate vaccines are manufactured.  Tennant et al. [58] have recently reported the 509 
development of “reagent strains” which have been specifically engineered for efficient 510 
purification of conjugate components from a single attenuated strain.  These reagent strains can 511 
then be used to develop homologous conjugate vaccines comprised of purified endotoxin-free 512 
core-O-polysaccharides (COPS) chemically conjugated to purified flagellin monomers.  Given 513 
the simplicity of the approach, this technique was applied to the engineering of reagent strains 514 
derived from both S. Typhimurium and S. Enteritidis pathogens.  The engineering of these 515 
reagent strains was accomplished with three key steps in which fully virulent pathogens were 516 
first rendered auxotrophic for guanine by deletion of the chromosomal guaBA locus, followed by 517 
a deletion of a master clpP regulatory locus which resulted in hyperflagellation of the reagent 518 
strain.  The final critical engineering step involved deletion of a FliD capping protein involved in 519 
the polymerization of flagellin monomers into fully functional flagella; in the absence of FliD, 520 
flagellin monomers were exported into the surrounding medium and could be efficiently purified 521 
away from intact bacteria.  When evaluated in mice, Simon et al. [59] observed that conjugate 522 
vaccines developed against S. Enteritidis generated robust flagellin-specific antibody responses 523 
and higher anti-LPS IgG responses than observed in mice immunized only with unconjugated 524 
COPS.  Most importantly, in mice challenged with fully virulent S. Enteritidis, conjugate vaccines 525 
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conferred 100% protection in vaccinated mice receiving fractional doses down to 0.25 g, and 526 
90% efficacy in mice immunized with as little as 25 ng of conjugate vaccine [60].  Genetically 527 
engineered reagent strains therefore represent a remarkably straightforward method from which 528 
highly immunogenic homologous flagellin-based conjugate vaccines can be safely and 529 
economically manufactured from a single attenuated strain. 530 
Engineered vaccines as interventions against cancer.  Another intriguing application of 531 
engineered strains targets development of therapeutic interventions against metastatic cancer.  532 
Vendrell et al. [61;62] have described in two recent studies, encouraging results using an 533 
engineered S.  Typhi attenuated vaccine candidate as a therapeutic intervention to promote 534 
tumor reduction when injected directly into the tumor and surrounding draining lymph nodes.  535 
This approach was used in mouse models of breast cancer [61] and T-cell lymphoma [62], and 536 
in both cases resulted in significant infiltration of activated neutrophils not observed with 537 
untreated tumors.  A reduction in invasion of tumor cells into nearby tissue, along with a 538 
reduction of potentially immunosuppressive Treg cells into the draining lymph nodes, 539 
accompanied delayed development of metastases and increased survival times in both studies 540 
as well.  In the case of immunotherapy against the mammary adenocarcinoma, significant 541 
infiltration of neutrophils was observed in necrotic areas that formed micro-abscesses [61].  542 
Remarkably, immunotherapy with the metastatic T-cell lymphoma resulted in complete tumor 543 
regression in 10% of treated animals (3 out of 30 treated), which engendered tumor-specific 544 
immunity when rechallenged with the homologous tumor (in 2 of the 3 re-challenged animals) 545 
[62].   Interestingly, although the attenuated vaccine strain was engineered to be dependent on 546 
guanine for growth, viable organisms were recovered from tumor tissues for up to 7 days after 547 
injection in both studies; it was hypothesized that a nutrient-rich environment required by a 548 
rapidly growing tumor might provide just enough benefit to vaccine organisms to enhance 549 
persistence, which could theoretically enhance antitumor inflammatory responses and promote 550 
tumor-specific cytotoxicity either directly or indirectly. 551 
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 In addition to therapeutic interventions, work has also progressed in the development of 552 
attenuated Salmonella carrier strains as therapeutic vaccines that target adaptive immunity in 553 
addition to innate immunity for resolution of tumors.  Xiong et al. [63] have reported the 554 
construction of attenuated S. Typhimurium carrier vaccines for intracellular delivery of an 555 
important tumor associated antigen, survivin, which is involved in tumor persistence, 556 
proliferation, and invasion [64].  In these carrier vaccines, delivery of survivin is accomplished by 557 
fusion to the T3SS SPI-2 effector protein SseF, which is translocated into host antigen 558 
presenting cells to elicit antitumor activity.  In this study, comparison of several strains 559 
combining various deletion mutations to achieve attenuation demonstrated that properly 560 
attenuated carrier vaccines were able to inhibit tumor growth in orally immunized mice 561 
subcutaneously challenged with colon carcinoma cells or challenged by intracranial injection of 562 
glioblastoma cells. The antitumor efficacy of these carrier vaccines was further improved in this 563 
work by enhancing innate immunity through intraperitoneal co-administration of a ligand 564 
adjuvant to stimulate natural killer T-cells [63]. 565 
 Live attenuated cancer vaccines have also shown promise in a Phase 1 clinical trial in 566 
which an attenuated strain of Listeria monocytogenes was evaluated in patients with late stage 567 
metastatic cervical cancer.  In this study [65], a streptomycin-resistant strain of L. 568 
monocytogenes was attenuated by chromosomal deletion of an essential gene encoding a 569 
master virulence regulator (PrfA), which was then placed on a multicopy plasmid to enhance 570 
plasmid retention in vivo.  Incomplete plasmid-based complementation of the chromosomal prfA 571 
deletion mutation was reported to attenuate pathogenicity by 4-5 logs [66].  This expression 572 
plasmid further encoded export of the human papillomavirus oncoprotein E7 (HPV-16 E7) fused 573 
to listeriolysin O [67].  The carrier vaccine proved somewhat reactogenic in all patients receiving 574 
intravenous infusions of two doses ranging from 1 x 109 to 1 x 1010 CFU and spaced three 575 
weeks apart.  However, 30% of patients experienced a reduction in tumor size, and overall 576 
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median survival was 347 days, versus a median survival time of 6-7 months for patients treated 577 
by more conventional methods. 578 
 579 
CONCLUSIONS 580 
 In this review, we have not attempted to provide an exhaustive recapitulation of 581 
engineering techniques and strategies currently available for constructing attenuated live strains 582 
and carrier vaccines.  Rather, we have been intentionally selective in citing examples that 583 
effectively illustrate the fundamental and central theme of this review in which we stress the 584 
importance of metabolic fitness and its impact on the immunogenicity and protective efficacy of 585 
live vaccines.  We have highlighted a wide array of engineering techniques and strategies which 586 
when properly and carefully applied can achieve the critical balance between safety and 587 
immunogenicity that ultimately determines the success or failure of live vaccines in clinical trials.  588 
We believe that with the availability of sufficient genomic data and armed with relevant data on 589 
mechanisms of pathogenicity, today’s vaccine developers may be constrained only by 590 
imagination and persistence in creating highly immunogenic live attenuated vaccines against an 591 
ever-increasing variety of emerging diseases of importance to public health. 592 
 593 
 594 
 595 
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 599 
 600 
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FIGURE LEGENDS 611 
Figure 1.  Balancing reactogenicity and immunogenicity in the development of live 612 
vaccines.  Both the safety and immunogenicity of a live bacterial strain are schematically 613 
represented in the left and right sides of each panel as a gradient of values.  For safety, the 614 
gradient extends from a region of unacceptable reactogenicity (red zone denoted by “R”) to a 615 
region of acceptable non-reactogenicity (green zone denoted by “NR”); similarly, for 616 
immunogenicity, the gradient extends from a region of minimal immunogenicity (red zone 617 
designated as non-immunogenic, “NI”) to the desired region of immunogenicity (green zone 618 
designated as immunogenic, “IM”).  Panels A-C schematically represent construction of a 619 
properly attenuated vaccine strain; and Panels D-F represent construction of a carrier vaccine 620 
expressing additional protective antigens from unrelated pathogens.  In this graphic, pathogenic 621 
organisms are represented by Panel A, over-attenuated vaccine strains engineered from 622 
pathogens are represented by Panel B, and properly engineered attenuated vaccines are 623 
represented by Panel C.  Given that expression of a foreign antigen can elevate metabolic 624 
burden and increase attenuation, starting with a slightly reactogenic vaccine candidate (Panel 625 
D) and over-expressing a foreign antigen (purple filled circle labeled “Ag”) will tip the balance 626 
and result in a safe but non-immunogenic live vaccine (Panel E), while expression of sufficient 627 
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levels of foreign antigen to elicit immunogenicity without over-attenuating the carrier strain will 628 
yield both a safe and immunogenic carrier vaccine (Panel F).  629 
 630 
Figure 2.  Strategies for developing safe and immunogenic carrier vaccines.  Candidate 631 
live vaccines are depicted as elongated circles, and the degree of attenuation is represented by 632 
shades of blue in which deep shades represent non-attenuated strains with shades becoming 633 
paler with increasing attenuation.  Production of foreign antigen is depicted as red dots.  634 
Immunization is represented as a black arrow extending across a vertical black line labeled 635 
“host barriers".  Panel A depicts conventional strategies in which an attenuated strain is 636 
engineered for tightly regulated expression of genes encoding foreign antigens after reaching 637 
inductive sites within the host, resulting in a burst of antigen synthesis and an increase in 638 
attenuation of the carrier vaccine.  Panel B depicts the combined strategies of Regulated 639 
Delayed Attenuation Phenotype (RDAP) and Regulated Delayed Antigen Synthesis (RDAS).  640 
Fully invasive carrier vaccines are used for immunization, which undergo limited replication and 641 
become increasingly attenuated with each round of replication (RDAP).  As replication proceeds 642 
and attenuation increases, synthesis of foreign antigen also begins to increase as vaccine 643 
organisms reach lymphoid inductive sites (RDAS).  Progression of both attenuation and antigen 644 
synthesis is inextricably linked in vivo to depletion of intracellular levels of arabinose as limited 645 
replication proceeds   (see text for further details).  Panel C depicts the combined strategies of 646 
RDAP and regulated delayed lysis to improve delivery of foreign antigens (or DNA vaccines) to 647 
immune inductive sites.  As replication proceeds and attenuation increases (RDAP), regulated 648 
induction of foreign antigen synthesis begins, accompanied by complete lysis and release of 649 
cytoplasmic contents into antigen presenting cells as vaccine organisms reach lymphoid 650 
inductive sites (see text for more details). 651 
 27 
REFERENCES 
 
 [1]  Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, multicentered 
trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following 
challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999 
Dec;67(12):6341-5. 
 [2]  Sabbagh SC, Forest CG, Lepage C, Leclerc JM, Daigle F. So similar, yet so different: uncovering distinctive 
features in the genomes of Salmonella enterica serovars Typhimurium and Typhi. FEMS Microbiol Lett 2010 
Apr;305(1):1-13. 
 [3]  Haraga A, Ohlson MB, Miller SI. Salmonellae interplay with host cells. Nat Rev Microbiol 2008 Jan;6(1):53-
66. 
 [4]  Srikanth CV, Mercado-Lubo R, Hallstrom K, McCormick BA. Salmonella effector proteins and host-cell 
responses. Cell Mol Life Sci 2011 Nov;68(22):3687-97. 
 [5]  Figueira R, Holden DW. Functions of the Salmonella pathogenicity island 2 (SPI-2) type III secretion system 
effectors. Microbiology 2012 May;158(Pt 5):1147-61. 
 [6]  Hansen-Wester I, Hensel M. Salmonella pathogenicity islands encoding type III secretion systems. Microbes 
Infect 2001 Jun;3(7):549-59. 
 [7]  Hindle Z, Chatfield SN, Phillimore J, et al. Characterization of Salmonella enterica derivatives harboring 
defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by 
immunization of healthy volunteers. Infect Immun 2002 Jul;70(7):3457-67. 
 [8]  Lyon CE, Sadigh KS, Carmolli MP, et al. In a randomized, double-blinded, placebo-controlled trial, the single 
oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming 
units. Vaccine 2010 Apr 30;28(20):3602-8. 
 [9]  Levine MM, Galen JE, Pasetti MF, Sztein MB. Attenuated strains of Salmonella enterica serovars Typhi and 
Paratyphi as live oral vaccines against enteric fever. In: Dougan G, Good MF, Liu MA, Nabel G, Nataro JP, 
Rappuoli R, et al., editors. New Generation Vaccines. 4 ed. New York, Informa Healthcare USA, 2010: p. 
497-505. 
[10]  Dilts DA, Riesenfeld-Orn I, Fulginiti JP, et al. Phase I clinical trials of aroA aroD and aroA aroD htrA 
attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000 Feb 
14;18(15):1473-84. 
[11]  Levine MM, Herrington D, Murphy JR, et al. Safety, infectivity, immunogenicity, and in vivo stability of two 
attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in 
humans. J Clin Invest 1987 Mar;79(3):888-902. 
[12]  Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella 
typhi vaccine strain in human volunteers. Vaccine 1996;14(1):19-24. 
[13]  Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and 
immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996;173(6):1408-14. 
 28 
[14]  Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, Curtiss R, III. Effect of deletion of genes involved in 
lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica 
serovar Typhimurium. Infect Immun 2011 Oct;79(10):4227-39. 
[15]  Murray GL, Attridge SR, Morona R. Altering the length of the lipopolysaccharide O antigen has an impact on 
the interaction of Salmonella enterica serovar Typhimurium with macrophages and complement. J Bacteriol 
2006 Apr;188(7):2735-9. 
[16]  Liu B, Knirel YA, Feng L, et al. Structural diversity in Salmonella O antigens and its genetic basis. FEMS 
Microbiol Rev 2013 Jul 13;10-6976. 
[17]  Resman N, Vasl J, Oblak A, et al. Essential roles of hydrophobic residues in both MD-2 and toll-like receptor 
4 in activation by endotoxin. J Biol Chem 2009 May 29;284(22):15052-60. 
[18]  Meng J, Lien E, Golenbock DT. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for 
receptor activation. J Biol Chem 2010 Mar;285(12):8695-702. 
[19]  Kong Q, Six DA, Liu Q, et al. Phosphate groups of lipid A are essential for Salmonella enterica serovar 
Typhimurium virulence and affect innate and adaptive immunity. Infect Immun 2012 Sep;80(9):3215-24. 
[20]  Sun W, Six D, Kuang X, Roland KL, Raetz CR, Curtiss R, III. A live attenuated strain of Yersinia pestis KIM 
as a vaccine against plague. Vaccine 2011 Apr 5;29(16):2986-98. 
[21]  Sun W, Six DA, Reynolds CM, Chung HS, Raetz CR, Curtiss R, III. Pathogenicity of Yersinia pestis synthesis 
of 1-dephosphorylated lipid A. Infect Immun 2013 Apr;81(4):1172-85. 
[22]  Curtiss R, III, Wanda SY, Gunn BM, et al. Salmonella enterica serovar typhimurium strains with regulated 
delayed attenuation in vivo. Infect Immun 2009 Mar;77(3):1071-82. 
[23]  Schleif R. AraC protein, regulation of the l-arabinose operon in Escherichia coli, and the light switch 
mechanism of AraC action. FEMS Microbiol Rev 2010 Sep;34(5):779-96. 
[24]  Li Y, Wang S, Scarpellini G, et al. Evaluation of new generation Salmonella enterica serovar Typhimurium 
vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci 
U S A 2009 Jan 13;106(2):593-8. 
[25]  Shi H, Santander J, Brenneman KE, et al. Live recombinant Salmonella Typhi vaccines constructed to 
investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS One 2010 Jun 
18;5(6):e11142. 
[26]  Frey SE, Lottenbach KR, Hill H, et al. A Phase 1 dose-escalation trial in adults of three recombinant 
attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen 
PspA. Vaccine 2013;In press. 
[27]  Pascual DW, Suo Z, Cao L, Avci R, Yang X. Attenuating gene expression (AGE) for vaccine development. 
Virulence 2013 Jul 1;4(5):384-90. 
[28]  Yang X, Thornburg T, Suo Z, et al. Flagella overexpression attenuates Salmonella pathogenesis. PLoS One 
2012;7(10):e46828. 
 29 
[29]  Cao L, Lim T, Jun S, Thornburg T, Avci R, Yang X. Vulnerabilities in Yersinia pestis caf operon are unveiled 
by a Salmonella vector. PLoS One 2012;7(4):e36283. 
[30]  Galán JE, Nakayama K, Curtiss III R. Cloning and characterization of the asd gene of Salmonella 
typhimurium:  use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 
1990;94:29-35. 
[31]  Pittard AJ. Biosynthesis of the aromatic amino acids. In: Neidhardt FC, Curtiss III R, Ingraham JL, Lin ECC, 
Low KB, Magasanik B, et al., editors. Escherichia coli and Salmonella:  cellular and molecular biology. 2 ed. 
Washington, D.C., ASM Press, 1996: p. 458-84. 
[32]  Curtiss R, III, Galan JE, Nakayama K, Kelly SM. Stabilization of recombinant avirulent vaccine strains in vivo. 
Res Microbiol 1990 Sep;141(7-8):797-805. 
[33]  Chase JW, Williams KR. Single-stranded DNA binding proteins required for DNA replication. Annu Rev 
Biochem 1986;55:103-36. 
[34]  Lohman TM, Ferrari ME. Escherichia coli single-stranded DNA-binding protein:  multiple DNA-binding modes 
and cooperativities. Annu Rev Biochem 1994;63:527-70. 
[35]  Galen JE, Wang JY, Chinchilla M, et al. A new generation of stable, nonantibiotic, low-copy-number plasmids 
improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect 
Immun 2010 Jan;78(1):337-47. 
[36]  Wang JY, Harley RH, Galen JE. Novel methods for expression of foreign antigens in live vector vaccines. 
Hum Vaccin Immunother 2013 Jul 1;9(7):1558-64. 
[37]  Bumann D. Regulated antigen expression in live recombinant Salmonella enterica serovar Typhimurium 
strongly affects colonization capabilities and specific CD4+-T-cell responses. Infect Immun 2001;69(12):7493-
500. 
[38]  Galen JE, Levine MM. Can a 'flawless' live vector vaccine strain be engineered? Trends in Microbiology 
2001;9(8):372-6. 
[39]  Galen JE, Pasetti MF, Tennant SM, Olvera-Ruiz P, Sztein MB, Levine MM. Salmonella enterica serovar 
Typhi Live Vector Vaccines Finally Come of Age. Immunol Cell Biol 2009 Jul;87(5):400-12. 
[40]  Curtiss R, III, Xin W, Li Y, et al. New technologies in using recombinant attenuated Salmonella vaccine 
vectors. Crit Rev Immunol 2010;30(3):255-70. 
[41]  Loessner H, Endmann A, Leschner S, et al. Improving live attenuated bacterial carriers for vaccination and 
therapy. Int J Med Microbiol 2008 Jan;298(1-2):21-6. 
[42]  Hegazy WA, Hensel M. Salmonella enterica as a vaccine carrier. Future Microbiol 2012 Jan;7(1):111-27. 
[43]  Wang S, Li Y, Scarpellini G, et al. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to 
enhance immunogenicity. Infect Immun 2010 Sep;78(9):3969-80. 
[44]  Wilson CJ, Zhan H, Swint-Kruse L, Matthews KS. The lactose repressor system: paradigms for regulation, 
allosteric behavior and protein folding. Cell Mol Life Sci 2007 Jan;64(1):3-16. 
 30 
[45]  Husnain SI, Thomas MS. The UP element is necessary but not sufficient for growth rate-dependent control of 
the Escherichia coli guaB promoter. J Bacteriol 2008 Apr;190(7):2450-7. 
[46]  Lewis C, Skovierova H, Rowley G, et al. Salmonella enterica serovar Typhimurium HtrA: regulation of 
expression and role of the chaperone and protease activities during infection. Microbiology 2009 Mar;155(Pt 
3):873-81. 
[47]  Kang HY, Curtiss R, III. Immune responses dependent on antigen location in recombinant attenuated 
Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 2003 Jul 
15;37(2-3):99-104. 
[48]  Galen JE, Zhao L, Chinchilla M, et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-
encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 
expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 2004 Dec;72(12):7096-
106. 
[49]  Galen JE, Chinchilla M, Pasetti MF, et al. Mucosal immunization with attenuated Salmonella enterica serovar 
Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody 
responses to parenteral PA83 vaccine. J Infect Dis 2009 Feb 1;199(3):326-35. 
[50]  Barat S, Willer Y, Rizos K, et al. Immunity to intracellular Salmonella depends on surface-associated 
antigens. PLoS Pathog 2012;8(10):e1002966. 
[51]  Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type 
III secretion system for vaccine development. Science 1998 Jul 24;281(5376):565-8. 
[52]  Hegazy WA, Xu X, Metelitsa L, Hensel M. Evaluation of Salmonella enterica type III secretion system effector 
proteins as carriers for heterologous vaccine antigens. Infect Immun 2012 Mar;80(3):1193-202. 
[53]  Kong W, Wanda SY, Zhang X, et al. Regulated programmed lysis of recombinant Salmonella in host tissues 
to release protective antigens and confer biological containment. Proc Natl Acad Sci U S A 2008 Jul 
8;105(27):9361-6. 
[54]  Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated 
immunization. Science 1995 Oct 13;270(5234):299-302. 
[55]  Sizemore DR, Branstrom AA, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated 
immunization. Vaccine 1997 Jun;15(8):804-7. 
[56]  Pasetti MF, Barry EM, Losonsky G, et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 
2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune 
responses and protection in cotton rats. J Virol 2003 May;77(9):5209-17. 
[57]  Kong W, Brovold M, Koeneman BA, Clark-Curtiss J, Curtiss R, III. Turning self-destructing Salmonella into a 
universal DNA vaccine delivery platform. Proc Natl Acad Sci U S A 2012 Nov 20;109(47):19414-9. 
[58]  Tennant SM, Wang JY, Galen JE, et al. Engineering and preclinical evaluation of attenuated nontyphoidal 
Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 2011 Oct;79(10):4175-
85. 
 31 
[59]  Simon R, Tennant SM, Wang JY, et al. Salmonella enterica serovar Enteritidis core O polysaccharide 
conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. 
enteritidis. Infect Immun 2011 Oct;79(10):4240-9. 
[60]  Simon R, Wang JY, Boyd MA, et al. Sustained protection in mice immunized with fractional doses of 
Salmonella enteritidis core and o polysaccharide-flagellin glycoconjugates. PLoS One 2013 May 
31;8(5):e64680. 
[61]  Vendrell A, Gravisaco MJ, Pasetti MF, et al. A novel Salmonella Typhi-based immunotherapy promotes 
tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model 
of breast cancer. Vaccine 2011 Jan 17;29(4):728-36. 
[62]  Vendrell A, Gravisaco MJ, Goin JC, et al. Therapeutic effects of Salmonella Typhi in a mouse model of T-cell 
lymphoma. J Immunother 2013 Apr;36(3):171-80. 
[63]  Xiong G, Husseiny MI, Song L, et al. Novel cancer vaccine based on genes of Salmonella pathogenicity 
island 2. Int J Cancer 2010 Jun 1;126(11):2622-34. 
[64]  Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012 
Apr;14(2):120-8. 
[65]  Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes 
vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 
2009 Jun;27(30):3975-83. 
[66]  Wallecha A, French C, Petit R, Singh R, Amin A, Rothman J. Lm-LLO-Based Immunotherapies and HPV-
Associated Disease. J Oncol 2012;2012:542851. 
[67]  Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors 
that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different 
T cell immunity that correlates with their ability to induce regression of established tumors immortalized by 
HPV-16. J Immunol 2001 Dec 1;167(11):6471-9. 
 
 
 
Figure 1-revised
Click here to download high resolution image
Figure 2
Click here to download high resolution image
